School of Medicine, Dentistry & Biomedical Sciences, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, N. Ireland.
Cancer Centre Belfast City Hospital, Lisburn Road, Belfast, BT9 7AB, N. Ireland.
CNS Oncol. 2022 Jun 1;11(2):CNS86. doi: 10.2217/cns-2021-0015. Epub 2022 May 23.
Glioblastoma (GBM) accounts for over 50% of gliomas and carries the worst prognosis of all solid tumors. Owing to the limited local control afforded by surgery alone, efficacious adjuvant treatments such as radiotherapy (RT) and chemotherapy are fundamental in achieving durable disease control. The best clinical outcomes are achieved with tri-modality treatment consisting of surgery, RT and systemic therapy. While RT-chemotherapy combination regimens are well established in oncology, this approach was largely unsuccessful in GBM until the introduction of temozolomide. The success of this combination has stimulated the search for other candidate drugs for concomitant use with RT in GBM. This review seeks to collate the current evidence for these agents and synthesize possible future directions for the field.
胶质母细胞瘤(GBM)占所有胶质瘤的 50%以上,是所有实体瘤中预后最差的。由于单独手术提供的局部控制有限,因此有效的辅助治疗(如放疗(RT)和化疗)对于实现持久的疾病控制至关重要。最佳的临床结果是通过手术、RT 和系统治疗的三模式治疗来实现的。虽然 RT-化疗联合方案在肿瘤学中已经确立,但直到替莫唑胺的引入,这种方法在 GBM 中基本上都没有成功。这种联合治疗的成功激发了人们对其他候选药物的探索,以期与 RT 联合用于 GBM。本综述旨在汇集这些药物的现有证据,并综合该领域未来可能的发展方向。